Eli Lilly & Co. is the first pharmaceutical stock to hit a $1 trillion valuation, with its stock’s rise driven by a methodical approach to capturing an obesity-drug market that didn’t exist five years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback